The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Phase 1 dosing is expected to finish by the end of 2025
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
AINU is set to accelerate its expansion footprint, enhance operational capabilities
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Subscribe To Our Newsletter & Stay Updated
